Liquid Biopsy Testing Solution with NGS

Genes2me Pvt Ltd08 May, 2026Health

Liquid biopsy, combined with next-generation sequencing (NGS), is transforming cancer detection by enabling non-invasive analysis of circulating tumour DNA (ctDNA) from a simple blood sample. Unlike traditional screening and tissue biopsies, this approach offers higher sensitivity, early detection, and real-time disease monitoring. With advancements in NGS, liquid biopsy can detect cancer-related mutations at very low levels, supporting early diagnosis and personalised treatment decisions. Solutions like Genes2Me’s liquid biopsy panels are helping bring this innovation into routine clinical practice, improving outcomes through earlier and more precise intervention.